A New Drug Against Severe Malaria

A New Drug Against Severe Malaria.
The decease class among children with severe malaria was nearly one-fourth lower when they received a new drug called artesunate than when they got the canon treatment of quinine, a new study shows. The finding suggests that artesunate should repay quinine as the malaria treatment of choice for severe malaria worldwide, the researchers said. Malaria, a c murrain that is transmitted via the bite of an infected mosquito, can quickly become life-threatening if left-hand untreated, according to the World Health Organization.

The new study included 5425 children with dangerous falciparum malaria - the most dangerous of four types of malaria affecting humans - in nine African countries. Of the children, 2713 were treated with artesunate and 2713 with quinine. There were 230 deaths (8,5 percent) in the artesunate bring and 297 deaths (11 percent) in the quinine group, the contemplation authors reported. That means the imperil of extermination was 22,5 percent lower for children who received artesunate. The investigators also found that side gear such as coma and convulsions were less frequent among those given artesunate.

The study authors, Nicholas White of Mahidol University in Bangkok, Thailand, and colleagues from the AQUAMAT reflect on group, also noted that while artesunate is more overpriced to buy, quinine is more expensive to administer. "A major factor restricting the deployment of artesunate has been unavailability of a commodity satisfying international good manufacturing standards. The most widely in use product, assessed in this study, does not yet have this certification, which has prevented deployment in some countries. This barrier must be rout speedily so that parenteral artesunate can be deployed in malaria-endemic areas to save lives," White's span wrote in a news release.